Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00984919 · ClinicalTrials.gov registry record
Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers
A clinical trial, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- 10
- Enrollment target
NCT00984919: Completed study, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT00984919 is a clinical trial that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00984919 has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at a biomarker, 11-dh-TXB2, in blood and urine samples from patients with prostate cancer and healthy volunteers.
Interventions
- OTHER laboratory biomarker analysis
- OTHER high performance liquid chromatography
- OTHER mass spectrometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-02 |
What the finished NCT00984919 record still lists
NCT00984919 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00984919 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00984919 about?
NCT00984919 is a clinical study titled "Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers". RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at a biomarker, 11-dh-TXB2, in blood and urine samples from patients with prostate cancer and healthy volunteers...
What is the current status of trial NCT00984919?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2009-11. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00984919?
The interventions under investigation include: laboratory biomarker analysis (OTHER), high performance liquid chromatography (OTHER), mass spectrometry (OTHER).
Who is sponsoring clinical trial NCT00984919?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia